With deep expertise in the GPCR field and a proprietary platform, we unlock the full therapeutic potential of GPCRs, including those previously considered challenging to target.
At Domain, we push boundaries. Our innovative drug discovery and development approach delivers GPCR-targeting therapies that modulate the immune system, ensuring optimal clinical development and maximum benefit for patients.
Each therapy is meticulously designed to deliver high efficacy and impact patient outcomes, thanks to precise positioning, clinical development strategy and its unique biological mechanisms. This strategic focus is particularly transformative for complex diseases in immuno-oncology and inflammation, two fields where GPCRs remain underexplored.
DT-9081 (EP4R antagonist)
DT-7012 (Anti-CCR8 antibody)
DT-9046 (Biased antagonist of PAR2)
Undisclosed GPCR targets
Our robust clinical-stage pipeline reflects over two decades of proven success, validated through partnerships with leading pharmaceutical companies and investors. This track record underscores the strength of our proprietary technology and unmatched expertise.
Domain’s ability to address complex GPCR biology at every step of drug discovery and development drives clinical strategies that tackle significant unmet medical needs in transformative ways.
Flagship programs, such as DT-9046, our first-in-class biased antagonist of PAR2,
and DT-7012, our best-in-class Treg depleting anti-CCR8 antibody, exemplify our innovative leadership in targeting challenging GPCRs. With highly differentiated profiles, these therapies are positioned to create significant value and establish a strong presence in a competitive, fast-growing markets.
| Discovery | Candidate | Preclinical | Phase I | Partner | |
|---|---|---|---|---|---|
|
DT-9081 - EP4 receptor antagonist
Solid Tumors + |
Phase I | ||||
|
DT-7012 - Anti-CCR8 depleting antibody
Solid Tumors + |
Preclinical | ||||
|
DT-9046 - Biased antagonist of PAR2
Inflammation + |
Preclinical | ||||
|
Undisclosed GPCR targets
+ |
Discovery | ||||
